Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 27, 2020 at 04:08 am
Share
Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 1,749.409 million compared to CNY 1,691.027 million a year ago. Operating income was CNY 314.759 million compared to CNY 309.653 million a year ago. Net income was CNY 269.569 million compared to CNY 261.818 million a year ago. Basic earnings per share from continuing operations was CNY 0.475 compared to CNY 0.449 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
HENAN LINGRUI PHARMACEUTICAL CO., LTD. 
